Absci Corp (ABSI) Stock Forecast & Price Target

Absci is attractive fundamentally because its AI-enabled Origin platform aims to compress antibody discovery and development by generating de novo candidates against previously unexplored epitopes while reducing screening library requirements by ~1,000-fold, which supports a scalable pipeline beyond a single asset. The investment case is anchored by ABS-201, whose prolactin receptor biology is supported by mechanistic evidence in both hair loss and endometriosis, including a preclinical endometriosis readout at SEUD 2026 showing significantly improved spontaneous movement (P=0.001) and tactile pain tolerance (P=0.0003) versus disease controls, with performance comparable to a GnRH hormonal comparator. Fundamentally, the upside thesis is strengthened by a large underpenetrated endometriosis market, prior human validation of PRLR blockade with HMI-115 in a randomized Phase 2 study (n=142) showing 42% dysmenorrhea pain reduction and 50% reduction in non-menstrual pelvic pain while preserving menstrual function, bone mineral density, and sex hormone levels, though the company remains early-stage with clinical, competitive, regulatory, and manufacturing risks.

Absci is fundamentally challenged by its heavy dependence on early-stage clinical validation, because the investment case for ABS-201 still rests on preclinical and Phase I/II data rather than any proven commercial or regulatory success, leaving significant clinical and regulatory execution risk. Although the current endometriosis data show meaningful unmet need and some encouraging efficacy signals, the same excerpt highlights that existing therapies already deliver substantial symptom relief in some settings, while ABS-201 has also shown a dose-dependent adverse-event profile with any adverse events rising to 75% at 240 mg versus 37% placebo, which could constrain differentiation and adoption. From a financial perspective, the company’s valuation framework is highly assumption-driven, using a DCF out to 2045 without terminal value and a 75% DCF / 25% Peak Multiple blend, underscoring that the stock’s thesis depends on distant, uncertain outcomes rather than near-term fundamental visibility.